OraSure Technologies 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- OraSure Technologies reported Q3 2026 revenue of $30.9 million, up 14% year over year and approximately 1% sequentially.
- Diagnostic products revenue was $16.8 million, up 16% year over year, driven by higher international HIV revenue, improved HCV performance, and continued SickleScan growth.
- Sample Management Solutions revenue was $12.5 million, up 21% year over year, driven by key commercial customer growth and order timing.
- GAAP gross margin increased to 45.2% from 43.5% in Q3 2025, while non-GAAP gross margin increased to 45.9% from 44.2%.
- GAAP operating loss was $13 million and non-GAAP operating loss was $10.2 million; the company ended the quarter with zero debt and $148.2 million in cash and cash equivalents.
- Operating cash flow was negative $10.9 million in Q3.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and welcome to the OraSure Technologies, Inc. 2026 third quarter earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question, you will need to press star 11 on your touchtone telephone. Please note, this call may be recorded. I would like to turn the call over to Mike Vallie in investor relations.
Please go ahead. Good afternoon, and welcome to OraSure Technologies third quarter 2026 earnings call.
Participating in the call for OTI are Carrie Eglinton Manner, our President and Chief Executive Officer, and Ken McGrath, our Chief Financial Officer. As a reminder, today's webcast is being recorded, and the recording can be found on our investor relations website. Before we begin, you should know that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share, cash flows, and other financial performance, product development, performance, shipments and markets, business plans, regulatory filings and approvals, expectations, and strategies. Actual results could be significantly different. Factors that could affect results are discussed more fully in OraSure's SEC filings, its annual report on Form 10-K for the year ended December 31, 2025, its quarterly reports on Form 10-Q, and its other SEC filings.
Although forward-looking statements help to provide more complete information about future prospects, listeners should keep in mind that forward-looking statements are based solely on information available to management as of today. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after this call. In addition, the call will also discuss certain non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in our earnings press release issued today, which is available on the investor relations section of our website. With that, I am pleased to turn the call over to Carrie.
Thanks, Mike, and thank you to everyone for joining us. Today, I will discuss some highlights from Q3 and provide updates on our key priorities for the balance of 2026 and our outlook for 2027. Q3 was another solid quarter of execution in our return to growth. We delivered 14% year-over-year growth and 1% sequential growth, meaningfully expanded gross margins, and reduced operating spend, results driven by continued execution of our strategy. Continuing now with more on each of our portfolios. In international diagnostics, our Q3 performance reflected our approach to stabilize, diversify, and localize our business. We are building on our longstanding leadership in HIV testing while expanding our portfolio and strengthening partnerships that broaden our reach and enable us to address critical public health needs across Africa, Latin America, and other international markets. Starting with Ebola. As discussed last quarter, in July, we received FDA emergency use authorization for our OraQuick Ebola 2.0 rapid antigen test.
The test detects all four Ebola virus species known to cause human disease, including Bundibugyo, the species responsible for the current outbreak. As of November 3, WHO reports that there are now more than 10,600 confirmed cases and nearly 5,200 deaths. Transmission has spread across multiple provinces in the Democratic Republic of the Congo and crossed international borders, including the first recorded cases in Kenya's history, as well as a case in Nigeria. Against this backdrop, the need for rapid decentralized diagnostic capacity is clear. Rapid testing can play an important role alongside surveillance, contact tracing, isolation, and other public health measures to identify cases quickly and help interrupt chains of transmission.
Our test is particularly well-suited for point-of-need deployment with its low infrastructure needs, speed, and ease of use. Following our FDA EUA, we have quickly fulfilled initial commercial orders for Ebola 2.0. We believe, however, that the more meaningful catalysts for broader adoption are still ahead of us. One important catalyst will be the results of the BRIDGE Access Platform study, which we've previously discussed. Led by Africa CDC and WHO with Unitaid support, the BRIDGE Access study is independently evaluating diagnostic products for the current Bundibugyo outbreak, with the evidence intended to inform Africa CDC recommendations as well as national and regional decisions regarding registration and introduction of diagnostic tests. This is an important example of how the public health environment in Africa is evolving post-pandemic and following the international aid cuts of 2025. African countries are increasingly focused on building greater self-reliance and locally led health security infrastructure.
Africa CDC itself has made local manufacturing, reduced dependency, and greater health sovereignty central elements of its health security agenda. That evolution means adoption increasingly occurs through African-led, country-specific pathways for evaluation, registration, procurement, and deployment. These include new processes that are taking time, even during an urgent outbreak, but they also reinforce the importance of the investments we have been making to localize our presence and capabilities in the region. To best serve Africa, OraSure has launched local assembly in Uganda, where our partner is already expanding access to our HIV products and has the potential to add Ebola and other products in the future. Nigeria is our next planned market for launching our localized approach in Africa. We believe we are well-positioned as the Ebola response moves into its next phase.
CDC currently assesses the most likely near-term scenario as a very large, sustained outbreak with high-intensity transmission in multiple areas, underscoring the immediate and continued need for a range of effective diagnostic tools. Our product can play an important role on the front lines and porous borders of this outbreak. Our manufacturing capability is ready, and we bring decades of experience and partnerships to readily serve the region's needs. Beyond this outbreak, we believe rapid point-of-need diagnostics can become an increasingly important component of outbreak preparedness and response, and that OraSure is ready and able to play a meaningful role as these pathways mature. Moving to sickle cell disease. We continue to support growing awareness and expansion of newborn screening across Africa, where Africa CDC estimates that 300,000 to 400,000 babies are born with sickle cell disease each year.
This momentum is driving increased demand for Sickle SCAN, and our successful integration of BioMedomics is enabling us to leverage our international commercial infrastructure to broaden access in markets with significant unmet need. We are also building partnerships with national and local health programs to expand point-of-need testing. Our recently announced partnership in Nairobi is one example, focused on scaling Sickle SCAN across community health centers and bringing testing closer to patients. At the same time, our participation in the World Coalition on Sickle Cell Disease connects OTI with leaders across government, healthcare, and patient advocacy to advance earlier diagnosis and strengthen testing pathways. We believe these relationships and joint efforts can help create the conditions for broader adoption of solutions like Sickle SCAN over time.
In summary, the ongoing progress of HIV, early momentum of Sickle SCAN, the potential of Ebola, plus the launch of our partners' nearshoring operations reflect the continued evolution of our international diagnostic strategy. We are successfully and increasingly pairing differentiated point-of-need diagnostics with localized capabilities and strong partnerships to expand access, diversify our business, and unlock new growth priorities. Over time, we believe this approach can continue to broaden our global reach, strengthen our competitive position, and enhance the durability of our growth. Switching to U.S. diagnostics. We delivered strong year-over-year growth, driven by strength in HCV, syphilis, and the continued underlying demand for HIV testing. Our syndemic testing strategy continues to be an important differentiator for us. With rapid testing solutions for HIV, HCV, and syphilis, we give customers a broader set of tools to reach populations that face multiple interconnected infectious disease risks.
We are very pleased with the progress of this strategy and the clinical and economic value it can deliver for our customers and the communities they serve. Turning to a regulatory process update on our InteliQuick CT/NG test on the Sherlock platform, intended as a first-of-its-kind rapid molecular self-test. We continue to work towards our resubmission with the FDA following our announcement of withdrawal in August. We are currently working within the pre-sub process, the aim of which is to align on the best path to regulatory access. We have valuable experience and feedback from our prior submission and are leveraging that, and this pre-sub process, to evaluate a range of pathways that can bring this important innovation to market. We remain confident in the product's performance, the impact it can have on patients, and our ability to navigate the regulatory landscape.
We will provide updates as we have more to share. Now moving to our sample management solutions portfolio. Growth from key commercial customers, along with the timing of orders, contributed to a strong Q3, with growth of more than 20% both year-over-year and sequentially. As announced last quarter, we received FDA clearance for our Colli-Pee Dx urine collection kit in June. We believe this technology can help expand access to STI testing through a more convenient and private approach to sample collection. We commercially launched the product in the third quarter and have been very encouraged by initial sales. At the same time, we are excited by the pipeline of potential customers who see real opportunities for the technology, both the chemistry and the device, with many evaluating the workflow required to incorporate self-collected urine into their testing programs.
This customer engagement reinforces our confidence in the opportunity for Colli-Pee Dx to support expanded access to STI testing over time. In Q3, we delivered strong growth in our SMS portfolio. Looking forward, our robust portfolio, the increased anticipated contributions from Colli-Pee and its NucleoPrecision chemistry, along with our partnerships with IVD platform manufacturers, reinforce our confidence in the long-term outlook for sample management solutions and its ability to contribute to our return to growth strategy. Overall, as we've outlined, OTI delivered a solid third quarter. We further demonstrated our return to growth, drove meaningful gross margin expansion, and continued to take cost out of the business. These results reflect the progress we are making in executing our strategy and positioning the business for sustainable growth and long-term value creation. With that, I'll turn the call over to Ken to discuss our financial results and guidance.
Thanks, Carrie. Total revenue in the third quarter was $30.9 million, growing 14% year-over-year and approximately 1% on a sequential basis. Diagnostic products generated $16.8 million of revenue in Q3, representing 16% year-over-year growth. The increase was driven by higher international HIV revenue, reflecting stabilization in our African markets and customer order timing, improved HCV performance supported by U.S. funding dynamics, and continued growth from Sickle SCAN. Sample management solutions revenue in Q3 was $12.5 million, a 21% year-over-year increase, driven by key commercial customer growth and timing of specific commercial orders. Our Q3 GAAP gross margin increased 173 basis points to 45.2% from 43.5% in the third quarter of last year. Non-GAAP gross margin in Q3 increased to 45.9% from 44.2%. The gross margin expansion was driven by operational efficiencies, resulting in improved overhead absorption, partially offset by geographic mix.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
